Ignite Creation Date:
2024-10-26 @ 3:40 PM
Last Modification Date:
2024-10-26 @ 3:40 PM
Study NCT ID:
NCT06607549
Status:
NOT_YET_RECRUITING
Last Update Posted:
None
First Post:
2024-09-13
Brief Title:
Loncastuximab Tesirine and Rituximab Following Stereotactic Radiosurgery SRS in Patients With Primary and Secondary Central Nervous System Lymphomas Lonca-R After SRS in CNSL
Sponsor:
None
Organization:
None
Study Overview
Official Title:
A Phase 1 Study of Loncastuximab Tesirine and Rituximab Following Stereotactic Radiosurgery SRS in Patients With Primary and Secondary Central Nervous System Lymphomas
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this clinical trial is to learn if drugs loncastuximab tesirine and rituximab lonca-R after stereotactic radiosurgery are safe and effective for treatment of central nervous system lymphomas
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None